798 results on '"Kimby, Eva"'
Search Results
202. Tumor burden status evaluated by computed tomography scan is of prognostic importance in patients with chronic lymphocytic leukemia
203. Clonal cell surface structures related to differentiation, activation and homing in B-cell chronic lymphocytic leukemia and monoclonal lymphocytosis of undetermined significance
204. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL
205. Update on Treatment Recommendations From the Fourth International Workshop on Waldenström's Macroglobulinemia
206. Functional signatures identified in B-cell non-Hodgkin lymphoma profiles
207. Phase II study of subcutaneous alemtuzumab without dose escalation in patients with advanced‐stage, relapsed chronic lymphocytic leukaemia
208. Rituximab Maintenance Treatment of Relapsed/Resistant Follicular Non- Hodgkin’s Lymphoma: Long-Term Outcome of the EORTC 20981 Phase III Randomized Intergroup Study
209. Long Term Responses to Fludarabine and Rituximab in Waldenstrom’s Macroglobulinemia
210. Preliminary Results of a Phase 1/2, Multi-Center, Open-Label Study (CLL- 001) Investigating a Stepwise Dose-Escalation Schedule of Lenalidomide in Relapsed or Refractory Chronic Lymphocytic Leukemia.
211. Expression of cannabinoid receptors type 1 and type 2 in non‐Hodgkin lymphoma: Growth inhibition by receptor activation
212. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden
213. Phase I study of a novel pro-apoptotic drug R-etodolac in patients with B-cell chronic lymphocytic leukemia
214. Mantle Cell Lymphoma Can Be Cured by Intensive Immunochemotherapy with In-Vivo Purged Stem-Cell Support; Final Report of the Nordic Lymphoma Group MCL2 Study.
215. Interim Results of a Phase I/II Study of Ocrelizumab, a New Humanised Anti-CD20 Antibody in Patients with Relapsed/Refractory Follicular Non-Hodgkin’s Lymphoma.
216. Grading Follicular Lymphoma: No Difference between 1, 2 and 3a, but 3b Is Something Else.
217. BCL-2/IgH PCR Values at the End of Induction Treatment Are Not Predictive for Progression Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized Phase III Intergroup Trial.
218. Therapy for patients with follicular lymphoma
219. Faculty Opinions recommendation of Bone marrow involvement in follicular lymphoma: comparison of histology and flow cytometry as staging procedures.
220. CD8+ T-Cell Content in Diagnostic Lymph Nodes Measured by Flow Cytometry Is a Predictor of Survival in Follicular Lymphoma
221. Characterization of genetic changes in MCL by interphase FISH on tissue sections
222. Two courses of four weekly infusions of rituximab with or without interferon-α2a: final results from a randomized phase III study in symptomatic indolent B-cell lymphomas.
223. Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
224. Strategies in the Management of Alemtuzumab-Related Side Effects
225. Cannabinoid receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma
226. Chimeric Anti-CD20 Monoclonal Antibody (Rituximab;Mabthera) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma: Final Analysis of a Phase III Randomized Intergroup Clinical Trial.
227. Tolerability and safety of rituximab (MabThera®)
228. The effect of ciprofloxacin on cyclophosphamide pharmacokinetics in patients with non-Hodgkin lymphoma
229. Polymorphisms in FcγRIIIA (CD16) Receptor Expression Are Associated With Clinical Response to Rituximab in Waldenström’s Macroglobulinemia
230. Mantle cell lymphomas with low levels of cyclin D1 long mRNA transcripts are highly proliferative and can be discriminated by elevated cyclin A2 and cyclin B1
231. Signaling Molecules and Cytokine Production in T Cells of Patients with B-Cell Chronic Lymphocytic Leukemia (B-CLL): Comparison of Indolent and Progressive Disease
232. T-Cells Present in Tumour Tissue May Affect the Outcome of Follicular Lymphoma.
233. Combination Therapy with Rituximab and Fludarabine in Waldenstrom’s Macroglobulinemia.
234. Portal Vein Thrombosis a Common Complication Following Splenectomy in Adults Patients with CLL or Myeloproliferative Disease.
235. Quantitative Pharmacogenetics of Cyclophosphamide in Patients with Hematological Malignancies.
236. Increased Risk for EBV-Lymphoma after Allogeneic Hsct in Adult Lymphoma Patients?A Retrospective Study of Reduced Compared to Myeloablative Conditioning.
237. Long-Term Complete Molecular Remissions in Untreated Symptomatic Follicular Lymphoma Treated with Rituximab as Single Agent and in Combination with Interferon-alpha-2a: Analysis of Minimal Residual Disease in the Randomized Phase II Study M39035.
238. Chimeric Anti-CD20 Monoclonal Antibody (Rituximab; Mabtheraâ) in Remission Induction and Maintenance Treatment of Relapsed /Resistant Follicular Non-Hodgkin’s Lymphoma : A Phase III Randomized Intergroup Clinical Trial.
239. Blood concentrations of alemtuzumab and antiglobulin responses in patients with chronic lymphocytic leukemia following intravenous or subcutaneous routes of administration
240. Safety of rituximab therapy during the first trimester of pregnancy: a case history
241. Posttransplant Lymphoma A Single-Center Experience of 500 Liver Transplantations
242. Uniform response criteria in Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia
243. Expression of serotherapy target antigens in Waldenstrom's macroglobulinemia: Therapeutic applications and considerations
244. Rituximab therapy for indolent non-Hodgkinʼs Iymphoma
245. High-dose cytarabine in upfront therapy for adult patients with acute lymphoblastic leukaemia
246. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)
247. Beyond immunochemotherapy: Combinations of rituximab with cytokines interferon-α2a and granulocyte-macrophage colony stimulating factor
248. Oral cladribine for B‐cell chronic lymphocytic leukaemia: report of a phase II trial with a 3‐d, 3‐weekly schedule in untreated and pretreated patients, and a long‐term follow‐up of 126 previously untreated patients
249. Cell surface expression of CD25, CD54, and CD95 on B‐ and T‐cells in chronic lymphocytic leukaemia in relation to trisomy 12, atypical morphology and clinical course
250. Both normal and leukemic B lymphocytes express multiple isoforms of the humanAiolos gene
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.